fbpx

The Second Annual Lyfebulb-Novo Nordisk Innovation Award

#LBNNAWARD17

The second Annual Lyfebulb-Novo Nordisk Innovation Summit and Award was a huge success! We just returned from a cold but sunny Copenhagen, Denmark, where 12 of the most innovative thinkers in diabetes management competed in a challenge in front of top Novo, Lyfebulb and other life sciences professionals, engaged with each other and point people at Novo Nordisk, and participated in work-shops and one-on-ones to both learn and teach.

The concept we created three years ago – patient entrepreneurship – has taken off, and what we saw last week was a true reflection of the idea that people living with disease or in close proximity of someone with the disease, can identify and solve for problems that may not be apparent to those with no connection beyond business and science. Diabetes is the first disease we have embarked on, for personal reasons, since I was diagnosed with T1D in 1989 and have been pursuing better solutions for myself and others since.

Our jury this year was strong, including top venture capitalists Shomit Gose (Managing Director ONSET Ventures) and Dr Magnus Persson (Chairman at Galecto BioTech and board professional), as well as leaders in diabetes treatment, Dr John Nolan (Special Advisor to the President at EASD) and Dr Shaukat Sadikot (President at the International Diabetes Foundation) and finally a patient representative, beautiful and smart, Vanessa Pirolo, T1D (board member ADJ Brazil).

In my opinion, it was very difficult to judge the finalists since they ranged widely across consumer products, coding, and medical devices, across genders, age and experience levels, and I found them to fall into three categories:

1: Investable opportunities for pure VCs

2: Partnering opportunities for healthcare companies

3: Community-platforms for awareness and advocacy

The winners, Amin Zayani of MedAngel – making sure the insulin we inject is functional, Linh Le (represented by Malcolm Nason) of Bonbouton – detecting foot ulcers before they occur, and Jen Horonjeff of Savvy Coop – connecting patients with companies to solve problems, represent the three categories and we applaud them for their inspiring presentations!

As a company focused on improving the quality of life for people with chronic disease, we see all the finalists as partners in our fight, and hope to work closely with them going forward.

In addition to the top three we have to mention the fabulous and gorgeous OneDrop (led by the ultimate diabadass, Jeff Dachis, digital marketing guru), our NYC friends Matt Loper, Wellth – using behavioral economics to improve outcomes, David Weingard, Fit4D – scaling CDEs and driving toward better glucose management, and close by in Connecticut, Charlie O’Connell, FitScript – making exercise safe for everyone with diabetes. More distant, but equally strong in their passion include French entrepreneur, Laurent Nicolas and DiabNext – simple solutions to monitor glucose and dose insulin through your phone, the highly energetic Australian, Josh Wulf, Magicraft – coding for children with diabetes, Canadian Aaron Horowitz and his Jerry the Bear, Sproutel – making a diabetes diagnosis become a super power for children, Fierce Liz Sacco with her inspiring story about developing a clever solution to clean up the blood post-monitoring with DiabeticDabs, and finally Slovenian Luca Zaponcic, CarbEasy and his smart scale to simplify carb-counting.

We cannot wait to see them all take next steps, raise more funds and further their projects toward success in the market place, since that means that patients all over the world will live a little better with their diabetes!

To investors reading this note – please let us know if you want more information about any of these companies – they are in fund-raising mode and we want them to succeed and you to make money while doing good for people with diabetes.

Finally, thank you Novo Nordisk, our fabulous partner who took a chance on us last year, and has shown such spirit and common Mission in our pursuit toward reducing the burden of diabetes everyday.

Karin

Patient Entrepreneur Amin Zayani of Med Angel BV Selected as the Winner of the 2017 Lyfebulb-Novo Nordisk Innovation Award

The Innovation Awards Recognize Patient Entrepreneurs for Their Innovative and Disruptive Ideas for Management of Diabetes Using Consumer, Medical Devices, or Healthcare Information Technologies

COPENHAGEN, Denmark, Nov. 08, 2017 (GLOBE NEWSWIRE) — Patient Entrepreneur and Founder & CEO of Med Angel BV, Amin Zayani was named the recipient of the 2017 Lyfebulb-Novo Nordisk Innovation Award for his work in addressing the management of diabetes and received a grant of $25,000. Amin Zayani was selected from a group of twelve finalists (which can be found here) after dozens of Award submissions were received from 25 countries. In addition, Linh Le, represented by Malcolm Nason, of Bonbouton and Jen Horonjeff of Savvy Cooperative received second and third place in the competition, and were awarded $15,000 and $10,000 respectively. The winners were selected by an international panel of judges.

The Summit jury was comprised of Magnus Persson, MD, PhD, a board professional, Professor John Nolan, Special Advisor to the President of EASD, Shaukat Sadikot, MD, President of the International Diabetes Foundation, Shomit Ghose, Partner at Onset Ventures (and the jury Chairman), and Vanessa Pirolo, a patient representative. Mr. Ghose, states:

“Diabetes is a global health issue affecting a diverse population. The Lyfebulb-Novo Nordisk Innovation Summit brought together diverse solutions from global innovators. As a venture capitalist, it was exciting for me to see all of the disruptive solutions that came forward.”

Amin Zayani, who took first place, described his reaction at being announced the winner:

“This prize represents a lot of recognition for our company’s mission and we are raising awareness of the importance of properly storing insulin at home. When one of the world leaders in making insulin recognizes the problem as well, it consolidates our case. I’m so happy and proud, this prize motivates me to continue what I’m doing.”

The Lyfebulb-Novo Nordisk Summit and Award spotlights outstanding Patient Entrepreneurs’ innovative ideas to disrupt the future management of Diabetes via consumer products, medical devices, or healthcare information technologies. The twelve finalists attended the 2017 Lyfebulb-Novo Nordisk Innovation Summit November 6-8, 2017 hosted by Novo Nordisk A/S in Copenhagen, Denmark, which provided a unique opportunity for visibility and recognition in this highly competitive arena. For more information please visit Lyfebulb’s website.

Dr. Karin Hehenberger, CEO and Founder of Lyfebulb states:

“This year’s Lyfebulb-Novo Nordisk Innovation Summit in Diabetes saw an increase in number of applications from a wider range of countries than last year. The interaction with the 12 finalists proved rewarding for all parties involved, including the distinguished jury, invited guests, Novo Nordisk, and Lyfebulb leadership. We congratulate the three winners chosen by our diverse jury. We believe, however, that all of the finalists have promising futures in this space, and above all, show that their personal ‘lived experiences’ are strong value-adds to the businesses they are building. Lyfebulb’s concept of empowering patient entrepreneurs and to bridge industry with patient communities was clearly validated through this Summit.”

Senior Vice President for Novo Nordisk Device R&D Kenneth Strømdahl adds:

“Entrepreneurial spirit is fueled by great ideas and passion, and patient communities provide vital insights into how we can foster patient-driven innovation. It was a great pleasure to engage with the 12 finalists and there is no doubt that we are all working towards the same goal to ultimately defeat diabetes.”

For more information, please visit Lyfebulb’s website.

Share2Print
November 08, 2017 09:14 ET | Source: Lyfebulb
COPENHAGEN, Denmark, Nov. 08, 2017 (GLOBE NEWSWIRE) — Patient Entrepreneur and Founder & CEO of Med Angel BV, Amin Zayani was named the recipient of the 2017 Lyfebulb-Novo Nordisk Innovation Award for his work in addressing the management of diabetes and received a grant of $25,000. Amin Zayani was selected from a group of twelve finalists (which can be found here) after dozens of Award submissions were received from 25 countries. In addition, Linh Le, represented by Malcolm Nason, of Bonbouton and Jen Horonjeff of Savvy Cooperative received second and third place in the competition, and were awarded $15,000 and $10,000 respectively. The winners were selected by an international panel of judges.

The Summit jury was comprised of Magnus Persson, MD, PhD, a board professional, Professor John Nolan, Special Advisor to the President of EASD, Shaukat Sadikot, MD, President of the International Diabetes Foundation, Shomit Ghose, Partner at Onset Ventures (and the jury Chairman), and Vanessa Pirolo, a patient representative. Mr. Ghose, states:

“Diabetes is a global health issue affecting a diverse population. The Lyfebulb-Novo Nordisk Innovation Summit brought together diverse solutions from global innovators. As a venture capitalist, it was exciting for me to see all of the disruptive solutions that came forward.”

Amin Zayani, who took first place, described his reaction at being announced the winner:

“This prize represents a lot of recognition for our company’s mission and we are raising awareness of the importance of properly storing insulin at home. When one of the world leaders in making insulin recognizes the problem as well, it consolidates our case. I’m so happy and proud, this prize motivates me to continue what I’m doing.”

The Lyfebulb-Novo Nordisk Summit and Award spotlights outstanding Patient Entrepreneurs’ innovative ideas to disrupt the future management of Diabetes via consumer products, medical devices, or healthcare information technologies. The twelve finalists attended the 2017 Lyfebulb-Novo Nordisk Innovation Summit November 6-8, 2017 hosted by Novo Nordisk A/S in Copenhagen, Denmark, which provided a unique opportunity for visibility and recognition in this highly competitive arena. For more information please visit Lyfebulb’s website.

Dr. Karin Hehenberger, CEO and Founder of Lyfebulb states:

“This year’s Lyfebulb-Novo Nordisk Innovation Summit in Diabetes saw an increase in number of applications from a wider range of countries than last year. The interaction with the 12 finalists proved rewarding for all parties involved, including the distinguished jury, invited guests, Novo Nordisk, and Lyfebulb leadership. We congratulate the three winners chosen by our diverse jury. We believe, however, that all of the finalists have promising futures in this space, and above all, show that their personal ‘lived experiences’ are strong value-adds to the businesses they are building. Lyfebulb’s concept of empowering patient entrepreneurs and to bridge industry with patient communities was clearly validated through this Summit.”

Senior Vice President for Novo Nordisk Device R&D Kenneth Strømdahl adds:

“Entrepreneurial spirit is fueled by great ideas and passion, and patient communities provide vital insights into how we can foster patient-driven innovation. It was a great pleasure to engage with the 12 finalists and there is no doubt that we are all working towards the same goal to ultimately defeat diabetes.”

For more information, please visit Lyfebulb’s website.

About Lyfebulb

Lyfebulb is a business focused on bridging patient communities with industry, and providing a strong voice to people living with chronic disease by empowering patient entrepreneurs and patient ambassadors. See www.lyfebulb.com, Facebook, Twitter, Instagram, Karin Hehenberger LinkedIn, and Lyfebulb LinkedIn.

About Novo Nordisk

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 42,000 people in 77 countries and markets its products in more than 165 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube

Source: Nasdaq Globe News Wire

Press Contact for Lyfebulb: 
Shepard Doniger
BDCG, Inc.
561-637-5750
sdoniger@bdcginc.com

LBNN Application Deadline is this Friday!

Greetings from the Nordic Life Science Days!

We are looking for the best patient entrepreneurs within diabetes consumer and medical devices, or healthcare information technology. Apply to be one of the ten finalists who will travel to Copenhagen, Denmark and attend the 2017 Lyfebulb-Novo Nordisk Innovation Summit and compete for monetary prizes!

Since applications close this Friday, September 15, we reflect upon the concept of patient entrepreneurship.

These people are exceptional individuals and they inspire others to an extent I have never seen before in the chronic disease community. They may not be climbing mountains, or cycling across the country, but instead, they are solving problems that we all encounter when living with a chronic condition.

Instead of waiting for others to help them as a patient, the patient entrepreneur finds solutions to everyday problems that are not always apparent to the mind of a scientist or business person, and they go out and start a business, build a product, and change the future for themselves and others! This can be done by finding a way to register when and how much insulin was dosed, bringing together people with chronic disease through technology and inventive models to change behavior, improving the look and feel of everyday medical devices, or just making certain items we eat or drink healthier and tastier.

This brings to market better products and it inspires all patients to take charge of their health and be less complacent – be less of a victim and more of a problem solver.

At Lyfebulb we ask people to take charge, to live beyond their disease or condition, and to utilize the patient experience when identifying solutions.

In contrast to organizations who monitor and describe patient experiences (all sensor companies and patient platforms), we offer solvers and solutions.

We inspire people to Live Lyfe – that is why our slogan is

“Turn Your Lyfe On”

Announcing the Lyfebulb-Novo Nordisk Innovation Award Winner!

The first Lyfebulb Novo-Nordisk Innovation Summit in Copenhagen, Denmark has wrapped! After a few jam-packed days that included dinners, workshops, speeches by Lyfebulb founder and CEO, Karin Hehenberger, and Novo Nordisk Senior Vice President, Device R&D, Kenneth Strømdahl, as well as pitches from each of our ten patient entrepreneur finalists, we have a WINNER!

Congratulations to Brianna Wolin, CEO and co-founder of Find Your Ditto, who received the first ever Lyfebulb-Novo Nordisk Innovation Award! Wolin’s company is a mobile platform for connecting individuals living with the same chronic illness locally for on-demand, in-person peer support.

b64a2226

“To be recognized by an innovative organization such as Lyfebulb and Novo Nordisk, a global pharmaceutical leader in diabetes care, is a true honor and an affirmation that our work to helping change the landscape surrounding isolation and depression in chronic illness communities is fully worthwhile,” said Brianna Wolin. “I’m so proud to have our mission – creating a world where no person living with a chronic illness ever has to feel alone – highlighted by this award.”

The competition was judged by five key opinion leaders and influences in the diabetes community, and Wolin was selected from a distinguished group of patient entrepreneur finalists that included:

  • Shilo Ben-Zeev, Smartzyme, Israel;
  • Jeff Dachis, OneDrop, USA;
  • Shantanu Gaur, MD, Allurion, USA;
  • Matt Loper, Wellth, USA;
  • Charles O’Connell, FitScript, USA;
  • Scott Smith, Socrates, USA;
  • Anna Sjoberg, Anna PS, Sweden;
  • John Sjolund, Patients Pending Ltd, UK;
  • David Weingard, Fit4D, USA.

We are very proud of all who participated! Every one of them is truly doing magnificent work in advancing the management and care of diabetes.

Once again, congratulations Brianna! We are looking forward to the growth and success of Find Your Ditto!

Lyfebulb Announces the Ten Finalists of the Lyfebulb-Novo Nordisk Innovation Award

annaeshoo

We are so proud to announce the ten finalists that will travel to Copenhagen, Denmark, to compete for the 2016 Lyfebulb-Novo Nordisk Innovation Award!!!

We received a ton of great applications from amazing patient entrepreneurs, but were tasked to narrow them down to ten.  We thank everyone that applied and admire the efforts of all patient entrepreneurs out there.

We formally made the announcement of the ten finalists this morning, and love the entrepreneurship, innovation, strength, and dedication they have shown throughout their careers to improve their lives, or the lives of loved ones, living with diabetes.

fullsizerender

Interests - Select all that apply